In summary, the aim of this study is to investigate the role of ITGβ3 and Hedgehog signaling in the development of trastuzumab resistance in HER2-positive breast cancer and to explore the potential of a combination therapy using trastuzumab and cilengitide to overcome this resistance. Here, ITGB3 is linked to breast carcinoma.